Abstract
Aim: To evaluate the efficacy and safety of transfusing leukoreduced red blood cells (LRBCs) and/or washed RBCs (WRBCs) in treating adult patients with autoimmune hemolytic anemia. Materials & methods: Randomized control trials were included. Outcomes were response incidence, hematological parameters (HPs) and adverse event (AE) incidence. Results: 16 randomized control trials (n = 1061) were included. LRBC+WRBC yielded increased response incidence and improvements in HP compared with suspended RBCs (SRBCs). WRBCs improved HP while LRBCs only improved RBC count and total bilirubin. LRBCs and WRBCs both reduce AE incidences compared with SRBCs. Conclusion: Modified blood components may achieve increased response incidence and/or HP, as well as decreased AE compared with SRBCs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
